Shire goes Viro
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
Shire is bolstering its rare diseases drug portfolio with a $4.2bn acquisition of ViroPharma. Lex's Nikki Tait and Vincent Boland discuss how this big buy fits with the pharmaceuticals company's cost drive.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
Shire is bolstering its rare diseases drug portfolio with a $4.2bn acquisition of ViroPharma. Lex's Nikki Tait and Vincent Boland discuss how this big buy fits with the pharmaceuticals company's cost drive.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes